Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Biotechnology

Healthcare
$17.22 +3.01%

+$0.81 today

Market cap
$1.76B
Beta
0.38
P/E (TTM)
-4.6
EPS (TTM)
-$6.06
52W Low $18.29High $42.37

Volume 3.12M

Average 1.81M

Fair Value & DCF

Compare our fair value with your own assumptions

Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

Intrinsic Alpha fair value

Locked

Current Price

$17.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Build your own valuation

Test an independent scenario and compare it with Intrinsic Alpha's estimate.

Sign in to use the DCF calculator

Free accounts get 5 valuations per week. Upgrade for more.

Sign in / Sign up

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A11 analysts
RevenueN/AN/A+22.8%
+15.2% (5yr)7 analysts
Net IncomeN/AN/AN/A
N/A7 analysts
EBITN/AN/AN/A
N/A7 analysts

Analysis

Recent growth has been strongest in Revenue at +22.8% over three years. Forward estimates point to Revenue at +15.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Estimates & History

Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.

Further estimates hidden. Sign in to unlock

Competitor Valuations

Peer stocks ranked by intrinsic value status

CompanyMarket CapPriceValuationP/E1Y Return

BridgeBio Pharma, Inc.

NASDAQ:BBIO

$15.25B$78.30Not rated-18.1+20.98%

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

$11.09B$57.23Undervalued39.4+17.04%

PTC Therapeutics, Inc.

NASDAQ:PTCT

$5.30B$63.49Undervalued-35.0-23.72%

uniQure N.V.

NASDAQ:QURE

$1.67B$23.81Not rated-14.1-27.49%

MeiraGTx Holdings plc

NASDAQ:MGTX

$881.67M$9.18Not rated-7.4+9.56%

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

$675.64M$12.23Not rated-4.0+3.68%

REGENXBIO Inc.

NASDAQ:RGNX

$505.18M$7.64Not rated-1.5-33.95%

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

$252.48M$2.30Not rated-1.7-25.70%

Abeona Therapeutics Inc.

NASDAQ:ABEO

$138.30M$2.42Not rated4.9-41.94%

Mereo BioPharma Group plc

NASDAQ:MREO

$49.10M$0.31Not rated-1.4-82.12%